The chorioallantoic membrane as a bio-barrier model for the evaluation of nanoscale drug delivery systems for tumour therapy

Adv Drug Deliv Rev. 2021 Jul:174:317-336. doi: 10.1016/j.addr.2021.04.022. Epub 2021 Apr 24.

Abstract

In 2010, the European Parliament and the European Union adopted a directive on the protection of animals used for scientific purposes. The directive aims to protect animals in scientific research, with the final goal of complete replacement of procedures on live animals for scientific and educational purposes as soon as it is scientifically viable. Furthermore, the directive announces the implementation of the 3Rs principle: "When choosing methods, the principles of replacement, reduction and refinement should be implemented through a strict hierarchy of the requirement to use alternative methods." The visibility, accessibility, and the rapid growth of the chorioallantoic membrane (CAM) offers a clear advantage for various manipulations and for the simulation of different Bio-Barriers according to the 3R principle. The extensive vascularisation on the CAM provides an excellent substrate for the cultivation of tumour cells or tumour xenografts which could be used for the therapeutic evaluation of nanoscale drug delivery systems. The tumour can be targeted either by topical application, intratumoural injection or i.v. injection. Different application sites and biological barriers can be examined within a single model.

Keywords: Biocompatibility; CAM; Cancer; Egg; Ex ovo; Ex vivo; Liposomes; Nanoparticles.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animal Use Alternatives
  • Animals
  • Antineoplastic Agents / administration & dosage
  • Chorioallantoic Membrane / drug effects*
  • Chorioallantoic Membrane / metabolism
  • Drug Delivery Systems*
  • Humans
  • Nanoparticles
  • Neoplasms / drug therapy*
  • Xenograft Model Antitumor Assays / methods

Substances

  • Antineoplastic Agents